Helus Pharma Inc (HELP)

11:47 AM

Helus Pharma’s top-line Phase II data signal detection study for HLP004 - The Pharma Letter

11:47 AM

10:38 AM

Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints - Benzinga

10:38 AM

10:36 AM

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - Investing News Network

10:36 AM

09:04 AM

HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism - Stocktwits

09:04 AM

09:02 AM

Helus Pharma (HELP) Shares Drop Despite Positive Phase 2 Trial Results - GuruFocus

09:02 AM

08:50 AM

Helus Pharma (HELP) Reports Positive Phase 2 Study Results for A - GuruFocus

08:50 AM

08:21 AM

Cybin’s Helus Pharma Posts Strong Phase 2 Data for HLP004 in Hard-to-Treat Anxiety - TipRanks

08:21 AM

08:18 AM

Helus stock falls on data for anxiety therapy (HELP:NASDAQ) - Seeking Alpha

08:18 AM

07:34 AM

Helus Pharma announces topline results in phase 2 signal detection study for Hlp004 in patients with generalized anxiety disorder - marketscreener.com

07:34 AM

07:33 AM

Helus Pharma Announces Topline Results In Phase 2 Signal Detection Study For Hlp004 In Patients With Generalized Anxiety Disorder - TradingView

07:33 AM

07:30 AM

Experimental anxiety drug helps 67% of hard-to-treat patients - Stock Titan

07:30 AM

Mar 03, 2026

symbol__ Stock Quote Price and Forecast - CNN

Mar 03, 2026

Mar 02, 2026

Helus Pharma (HELP) Price Target Raised by HC Wainwright & Co. | - GuruFocus

Mar 02, 2026

Feb 27, 2026

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - The AI Journal

Feb 27, 2026

Feb 27, 2026

Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders - The Malaysian Reserve

Feb 27, 2026

Feb 26, 2026

From Lab to Clinic: Five CNS Companies Advancing Neuroscience Treatments - Baystreet.ca

Feb 26, 2026

Feb 25, 2026

Helus Pharma appoints Dr. Freda Lewis-Hall to board of directors - Investing.com India

Feb 25, 2026

Feb 24, 2026

HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience - Seeking Alpha

Feb 24, 2026

Feb 24, 2026

Helus Pharma (Nasdaq: HELP) brings former Pfizer CMO Lewis-Hall onto board - Stock Titan

Feb 24, 2026

Feb 24, 2026

Helus Pharma appoints former Pfizer chief medical officer to board of directors - marketscreener.com

Feb 24, 2026

Feb 24, 2026

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee - Toronto Star

Feb 24, 2026

Feb 20, 2026

Magic Mushrooms, Hard Cash: Compass Pathways' Trial Win, Fast Raise - Finviz

Feb 20, 2026

Feb 19, 2026

Cybin (Helus Pharma) Names Veteran Pharma Executive Michael Cola as CEO to Drive CNS Growth - The Globe and Mail

Feb 19, 2026

Feb 19, 2026

HELP Stock Price and Chart — NEO:HELP - TradingView

Feb 19, 2026

Feb 18, 2026

Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers - Finviz

Feb 18, 2026

Feb 18, 2026

Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth Drivers - Yahoo Finance

Feb 18, 2026

Feb 18, 2026

Industry veteran Michael Cola named Cybin (CYBN) chief executive - Stock Titan

Feb 18, 2026

Feb 18, 2026

Psychedelics stocks rise as Compass’ psilocybin drug heads to FDA - BioPharma Dive

Feb 18, 2026

Feb 17, 2026

Helus Pharma reports positive phase 2a trial results for depression drug - Investing.com Australia

Feb 17, 2026

Feb 17, 2026

Cybin stock surges after positive Phase 2a trial results for depression drug - Investing.com

Feb 17, 2026

Feb 17, 2026

HELP SEC FilingsCybin Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Feb 17, 2026

Feb 17, 2026

Cybin Inc.Common Stock (Nasdaq:HELP) Stock Quote - The Chronicle-Journal

Feb 17, 2026

Feb 17, 2026

HELP Stock Rallies After Experimental Depression Drug Reduces Symptoms In Study: Retail Thinks Its ‘Time To Buy More’ - Stocktwits

Feb 17, 2026

Feb 17, 2026

Helus gains on published data for psychedelic drug (HELP) - Seeking Alpha

Feb 17, 2026

Feb 17, 2026

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder - Investing News Network

Feb 17, 2026

Feb 17, 2026

Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder - Toronto Star

Feb 17, 2026

Feb 13, 2026

Helus Pharma To Report Phase 2 Data For HLP004 In Generalized Anxiety Disorder This Quarter - Nasdaq

Feb 13, 2026

Feb 13, 2026

Helus Pharma (HELP) Advances Neuro Portfolio with Robust Financi - GuruFocus

Feb 13, 2026

Feb 13, 2026

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Investing News Network

Feb 13, 2026

Feb 13, 2026

Cybin (Helus Pharma) Posts Higher Assets, Equity and Losses in Q3 FY2026 SEC Filing - TipRanks

Feb 13, 2026

Feb 13, 2026

Helus Pharma (NASDAQ: HELP) widens loss while sharply increasing cash - Stock Titan

Feb 13, 2026

Feb 11, 2026

Helus Pharma appoints Michael Cola as CEO - The Pharma Letter

Feb 11, 2026

Feb 11, 2026

HELUS PHARMA NAMES MICHAEL COLA AS CEO FOR NEXT PHASE OF GROWTH - Bernama

Feb 11, 2026

Feb 11, 2026

Helus Pharma Names Michael Cola As CEO For Next Phase Of GrowthBERNAMA - BERNAMA - Malaysian National News Agency

Feb 11, 2026